Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 16/20 | 0.69 |
| ▸ | RPS6KA1 | Q15418 | 13/20 | 0.69 |
| ▸ | RPS6KA5 | O75582 | 4/20 | 0.69 |
| ▸ | ROCK1 | Q13464 | 14/20 | 0.63 |
| ▸ | AKT2 | P31751 | 6/20 | 0.55 |
| ▸ | AKT3 | Q9Y243 | 2/20 | 0.55 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL5067615 | 0.98 | AKT1 (0.72) | AKT1RPS6KA1RPS6KA5ROCK1AKT2 | |
| SCHEMBL4065312 | 0.93 | AKT1 (0.77) | AKT1RPS6KA1RPS6KA5ROCK1AKT2 | |
| Trifluoroacetic Acid SCHEMBL5062857 | 0.92 | AKT1 (0.81) | AKT1RPS6KA1RPS6KA5ROCK1AKT2 | |
| Trifluoroacetic Acid SCHEMBL5062784 | 0.91 | AKT1 (0.80) | AKT1RPS6KA1RPS6KA5ROCK1AKT2 | |
| Trifluoroacetic Acid SCHEMBL5062549 | 0.91 | AKT1 (0.64) | AKT1RPS6KA1RPS6KA5ROCK1AKT2 | |
| SCHEMBL4068592 | 0.90 | AKT1 (0.81) | AKT1RPS6KA1RPS6KA5ROCK1AKT2 | |
| Trifluoroacetic Acid SCHEMBL5063576 | 0.90 | AKT1 (0.85) | AKT1RPS6KA1RPS6KA5ROCK1AKT2 | |
| Trifluoroacetic Acid SCHEMBL5062285 | 0.89 | AKT1 (0.73) | AKT1RPS6KA1RPS6KA5ROCK1AKT2 | |
| Trifluoroacetic Acid SCHEMBL5066060 | 0.88 | AKT1 (0.61) | AKT1RPS6KA1RPS6KA5ROCK1AKT2 | |
| Trifluoroacetic Acid SCHEMBL5058517 | 0.87 | AKT1 (0.78) | AKT1RPS6KA1RPS6KA5ROCK1AKT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255143-A1 | Inhibitors of Akt Activity | SMITHKLINE BEECHAM CORPORATION (PA) | 2008-10-16 | — | — | US | disclosed |
| US-20070161665-A1 | Cancer treatment method | SMITHKLINE BEECHAM CORPORATION | 2007-07-12 | — | — | US | disclosed |
| EP-1682123-A1 | CANCER TREATMENT METHOD | SmithKline Beecham (Cork) Limited (IE) | 2006-07-26 | — | — | EP | disclosed |
| WO-2005046678-A1 | CANCER TREATMENT METHOD | SMITHKLINE BEECHAM (CORK) LIMITED (IE) | 2005-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255143-A1 | Inhibitors of Akt Activity | PI4KB, PIK3CA, AKT2 | AKT1 5/4885RPS6KA1 127/4885RPS6KA5 156/4885 |
| US-20070161665-A1 | Cancer treatment method | ERBB2, EGFR, PIK3CA | AKT1 24/4885RPS6KA1 185/4885RPS6KA5 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.